Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MXCT vs ISPC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
MXCT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–3 Matrix Metrics)
MXCT Overall Winner
6-Pillar Tally: MXCT 3 – 2 ISPC (1 Tie)
Matrix Metrics: MXCT 4 – 3 ISPC
As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over iSpecimen Inc. (ISPC) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas ISPC carries 41.6/100 (SELL) at $0.46 (N/M Forward P/E, -1455.3% operating margin).
- Growth vs. Quality Trade-Off: MXCT earns the overall head-to-head edge with a stronger Unified Composite Score (41.7/100 SELL vs. ISPC 41.6/100 SELL) and 1.19β · 96% Vol risk profile, whereas ISPC leads top-line expansion (+128.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
- Defensive Composite Rating Caution: Although MXCT compares more favorably head-to-head, both MXCT (41.7/100 SELL) and ISPC (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
- Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile ISPC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MXCT vs ISPC
MXCT
Head-to-Head Winner
MaxCyte, Inc. Common Stock
$1.37
+7.03% 1D
Market Cap
$132.2M
TTM Revenue
$34M
Forward P/E
N/M
Beta / 30D Vol
1.19β · 96% Vol
Unified Composite Score
41.7
SELL
Tech 46.0
Fund 52.0
Flow 62.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
ISPC
iSpecimen Inc. Common Stock
$0.46
-13.58% 1D
Market Cap
$3.1M
TTM Revenue
$603,744
Forward P/E
N/M
Beta / 30D Vol
-10.07β · 74% Vol
Unified Composite Score
41.6
SELL
Tech 25.0
Fund 43.0
Flow 50.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (MXCT 3 – 2 ISPC)
1. Valuation Multiples
ISPC
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
3.9x
0.8x
2. Growth & Scale
MXCT
Revenue Growth (YoY)
+48.7%
+128.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$34M
$603,744
Market Cap
$132.2M
$3.1M
3. Profitability & Quality
MXCT
Gross Margin
81.0%
-42.1%
Operating Margin
-85.5%
-1455.3%
Net Profit Margin
-81.4%
0.0%
Return on Equity (ROE)
-16.9%
-303.9%
4. Balance Sheet & Cash Flow
ISPC
Cash Generation (TTM)
-$24M
-$8.7M EBITDA
Cash Flow Margin
-69.2%
N/A
Net Cash / Leverage
$2.2M Net Debt (0.11x D/E)
$2.6M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
MXCT
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MXCT (4) vs ISPC (3)| Institutional Metric | MXCT | ISPC | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $132.2M | $3.1M | MXCT | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +48.7% | +128.9% | ISPC | |
| Operating Margin (TTM) | -85.5% | -1455.3% | MXCT | |
| Net Profit Margin | -81.4% | 0.0% | ISPC | |
| Return on Equity (ROE) | -16.9% | -303.9% | MXCT | |
| 52-Week Range Position | 63% ($1–$2) | 5% ($0–$7) | MXCT | |
| Beta / 30D Volatility | 1.19β · 96% Vol | -10.07β · 74% Vol | ISPC | |
| Unified Institutional Score | 41.7 / 100 (SELL) | 41.6 / 100 (SELL) | Tie | |
| Trailing 12M Revenue (USD) | $34M | $603,744 | Scale | |
| Gross Profit Margin (TTM) | 81.0% | -42.1% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.9x EV/Rev | N/M PEG · 0.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$24M ($2.2M Net Debt (0.11x D/E)) | -$8.7M EBITDA ($2.6M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
MXCT +41.0 pp
3M Horizon
MXCT +69.5 pp
6M Horizon
MXCT +118.5 pp
1Y Horizon
ISPC +9.41 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MXCT Revenue | ISPC Revenue | MXCT Op. Margin | ISPC Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | N/A | -93.7% | N/A | MXCT |
| FY2020 | $20M | $10M | -71.6% | -29.4% | ISPC |
| FY2021 | $20M | $10M | -84.3% | -53.2% | ISPC |
| FY2022 | $30M | $10M | -95.2% | -97.9% | MXCT |
| FY2023 | $20M | $10M | -247.7% | -112.5% | ISPC |
| FY2024 | $20M | $10M | -230.5% | -137.0% | ISPC |
| FY2025 | $20M | $0M | -247.6% | -465.4% | MXCT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MXCT
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ISPC
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ISPC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MXCT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ISPC Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ MXCT vs ISPC Key Questions & Quantitative Answers
As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over iSpecimen Inc. (ISPC) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas ISPC carries 41.6/100 (SELL) at $0.46 (N/M Forward P/E, -1455.3% operating margin). Growth vs. Quality Trade-Off: MXCT earns the overall head-to-head edge with a stronger Unified Composite Score (41.7/100 SELL vs. ISPC 41.6/100 SELL) and 1.19β · 96% Vol risk profile, whereas ISPC leads top-line expansion (+128.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although MXCT compares more favorably head-to-head, both MXCT (41.7/100 SELL) and ISPC (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile ISPC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MXCT leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with ISPC at +128.9% YoY revenue growth and +0.0% YoY earnings growth on $603,744 TTM revenue (-42.1% gross margin, -1455.3% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), MXCT cumulative revenue shifted +100.0% while ISPC shifted +0.0%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ISPC.
ISPC screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas ISPC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus ISPC (-303.9% ROE) capital efficiency.
In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, ISPC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-10.07β · 74% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ISPC vs MXCT · Reverse Pair
MXCT vs CTKB
· Sector Peer
MXCT vs SGHT
· Sector Peer
MXCT vs TMCI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking